Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vesatolimod in Virally-Suppressed Chronic Hepatitis B
NCT02166047Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2014
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of vesatolimod in Chronic Hepatitis B (CHB), sponsored by Gilead Sciences. Started Jun 2014; status: completed.
02
Drugs
vesatolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02166047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02166047.